

## Making a difference for women with gynaecological cancer

Secretariat: Room: Bristol

**Wednesday 29<sup>th</sup> March 2017**

9.00am – 10.45am	90mins	Tumour Type Working Groups – Ovarian <b>Room: Mayfair 1</b>	Tumour Type Working Groups - Cervical <b>Room: Mayfair 2</b>	Tumour Type Working Groups – Endometrial <b>Room: Mayfair 3</b>	
<b>10.45am-11.00am</b>	<b>15mins</b>	<b>Morning Tea</b>			
11.00am -12.30pm	90 mins	RESEARCH ADVISORY COMMITTEE (RAC) Meeting			<b>Room: Mayfair 1</b>
<b>12.30 – 1.30pm</b>	<b>30 mins</b>	<b>Lunch</b>			
12.30pm – 3.15pm	150 mins	Board Meeting :			<b>Grosvenor 1 &amp; 2</b>
1.30pm-3.00pm	90 mins	<b>PURE SCIENCE SYMPOSIUM- SESSION CHAIRS – PAM POLLOCK AND ELAINE SANIJ</b> <b>MAYFAIR 1</b>			<b>EDUCATION FOR STUDY COORDINATORS – SUE BREW</b> <b>MAYFAIR 3</b>
1.30pm – 1.50pm	20 min	Novel insights into the renin-angiotensin system in endometrial cancer: <b>Kirsty Pringle</b>			<b>GCP TRAINING – ELEANOR ALLAN, CALEDONIAN CLINICAL TRAINING</b>  <b>BI-ANNUAL UPDATE CERTIFICATE TRAINING FOR STUDY COORDINATORS, NURSES, CLINICIANS</b>
1.50pm – 2.10pm	20 min	Characterizing acquired chemoresistance in HGSC: <b>Liz Christie</b>			
2.10pm – 2.30pm	20 min	Response and Resistance to PARP inhibitors: Beyond BRCA1/2: <b>Clare Scott</b>			
2.30pm – 2.40 pm	10 min	Meta-analysis of genome-wide association data for 78,683 women by the Endometrial Cancer Association Consortium (ECAC) identifies eight new genetic risk regions for endometrial cancer: <b>Tracy O'Mara</b>			
2.40pm – 2.50 pm	10 min	Distinct patterns of expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer point to a role for the stroma in metastasis: <b>Claire Henry</b>			
2.50pm – 3.00pm	10 min	Q&A or Panel			

<b>3.00pm – 3.30pm</b>	<b>30 mins</b>	<b>Afternoon Tea</b>	
3.30pm -5.00pm	80 mins	<b>PURE SCIENCE SYMPOSIUM – SESSION CHAIRS – CLARE SCOTT AND NIKOLA BOWDEN</b> <b>ROOM : MAYFAIR 1</b>	<b>GCP TRAINING -</b>  <b>ROOM: MAYFAIR 3</b>
3.30pm – 3.50pm	20 min	Stem/progenitor cells in the normal endometrium and endometrial cancer: <b>Caroline Gargett</b>	
3.50pm – 4.10pm	20 min	Exploring the genomic landscape of mucinous ovarian tumours: <b>Kylie Gorringe</b>	
4.10pm – 4.30pm	20 min	Pooled analyses from the Epidemiology of Endometrial Cancer Consortium (E2C2): how do breast feeding and NSAID use influence endometrial cancer risk?: <b>Susan Jordan</b>	
4.30pm – 4.40pm	10 min	Syk activity determines invasiveness and its nuclear level is associated with poor survival in Ovarian Cancer: <b>Yu Yu</b>	
4.40pm – 4.50pm	10 min	Inhibition of histone methyltransferases as novel targets for ovarian cancer therapy: <b>Jason Lee</b>	

## Wednesday 29<sup>th</sup> March 2017

5.15 – 5.45pm	30 mins	Sponsors Briefing	<b>ROOM: FOYER</b>
6.30 – 9.00pm		Depart Hyatt at 6.00pm by Bus (20-30mins)  <b>Welcome Reception &amp; Presentation &amp; Tour</b> <b>Peter MacCallum at the new Victorian Comprehensive Cancer Centre, Parkville</b>	

## Thursday 30<sup>th</sup> March 2017

6.45 -7.45am		Consumer led <b>Health and Fitness Session</b> 'Go step for Gynae' – gather in hotel outdoor forecourt, next to Reception.	
8.30 – 8.45 am	15 mins	Official Welcome & ANZGOG Update : Alison Brand ANZGOG Chair	
8.45-10.00AM	75MINS	<b>MAKING A DIFFERENCE FOR WOMEN WITH GYNAECOLOGICAL CANCER</b> <b>SESSION CHAIRS – PETER SYKES AND PEARLY KHAW</b> <b>ROOM: SAVOY 1</b>	
8.45 - 9.10am	25 mins	A framework for personalized approaches to ovarian cancer: <b>Anil Sood</b>	
9.10 – 9.35am	25 mins	Ovarian clear cell carcinomas: challenges and opportunities: <b>David Tan</b>	
9.35 – 10.00am	25 mins	Combined modality treatment in rare gynaecological cancers: <b>Remi Nout</b>	
10.00 – 10.30am	30 mins	<b>Morning Tea in the Exhibition Area</b>	
10.30 – 12.00PM	90 MINS	<b>IMPROVING CLINICAL PRACTICE FOR WOMEN WITH CANCER</b> <b>SPONSORED BY ROCHE</b> <b>SESSION CHAIR - SUMI ANANDA AND DEB NEESHAM</b> <b>ROOM: SAVOY 1</b>	
10.30 – 10.50am	20 mins	Improving clinical practice in fertility preservation: <b>Kate Stern</b>	
10.50 – 11.10am	20 mins	International Game changing clinical trials- present and future: <b>Bradley Monk</b>	
11.10 – 11.30am	20 mins	Immunotherapy- promise, potential and pitfalls: <b>George Au-Yeung</b>	
11.30 – 11.45am	15 mins	Prognostic role of histologic tumour regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma: <b>Paul Cohen</b>	
11.45 – 12.00pm	15 mins	Incidence of hypersensitivity reactions to paclitaxel with intravenous versus oral dexamethasone pre-medication: <b>Linda Mileschkin</b>	
12.00 – 1.00pm	60 mins	<b>LUNCH</b>	<b>Consumer Committee Bristol 1 / Quality Assurance Bristol 2 / Study Coordinators Connaught</b>

## Thursday 30<sup>th</sup> MARCH 2017

<b>1.00 – 2.30pm</b>	<b>90 mins</b>	<b>TRIAL UPDATE</b>	<b>SESSION CHAIR – LINDA MILESHKIN, RAC CHAIR , ALISON DAVIS, RAC DEP CHAIR</b>	<b>ROOM: SAVOY 1</b>
1.00 – 1.10pm	10mins	1 PARAGON – PI <b>Michael Friedlander</b>		
1.10 – 1.20pm	10 mins	2. OUTBACK – PI <b>Linda Mileskin</b>		
1.20 – 1.30pm	10mins	3. REZOLVE – PI <b>Katrin Sjoquist</b>		
1.30 – 1.40pm	10mins	4. ECHO – PI <b>Sandi Hayes presented by Martin Stockler</b>		
1.40 – 1.50pm	10mins	4. FEMME – PI <b>Andreas Obermair presented by Vanessa Taylor</b>		
1.50 – 2.00pm	10mins	5. VELIA – PI <b>Michael Friedlander</b>		
2.00 – 2.10pm	10 mins	6. MOST – PI <b>Michael Friedlander</b>		
2.10- 2.20pm	10 mins	7. PHAEDRA – PI <b>Yoland Antill</b>		
2.20 – 2.30pm	10 mins	8. STATEC: PI <b>Alison Brand</b>		
<b>2.30-3.00pm</b>	<b>30 mins</b>	<b>Afternoon Tea</b>		
<b>3.00-4.00pm</b>	<b>60mins</b>	<b>REDUCING THE CANCER BURDEN</b>	<b>SPONSORED BY SEQRIS</b>	
			<b>SESSION CHAIR – PETER GRANT &amp; CHRISTOPHER STEER</b>	<b>ROOM: SAVOY 1</b>
3.00 - 3.20pm	20 mins	Reducing the cervical cancer burden among Aboriginal and Torres Strait Islander women: <b>Lisa Whop</b>		
3.20 – 3.40pm	20mins	Leading the cervical cancer prevention revolution: Australia's new cervical screening approach in the HPV vaccine eras: <b>Julia Brotherton</b>		
3.40 – 4.00pm	20mins	Cancer Pathway Development in Australia, , Cancer Chief Advisor VIC Govt : <b>Rob Thomas</b>		
<b>4.00 – 4.30pm</b>	<b>30mins</b>	<b>OASIS PROGRAM TRIAL UPDATE</b>		<b>ROOM: SAVOY 1</b>
			<b>SESSION CHAIR - MICHAEL FRIEDLANDER AND ANNA DEFAZIO</b>	
4.00 – 4.10pm	10mins	1. MOCCA – PI <b>Michael Friedlander</b>		
4.10 – 4.20pm	10 mins	2. VIPS – PI <b>Linda Mileskin</b>		
4.20 – 4.30pm	10mins	3. CYCLIN-E1 – PI <b>Danny Rischin</b>		
<b>4.30 - 5.00pm</b>	<b>30mins</b>	<b>TRANSLATIONAL ANZGOG   TR-ANZGOG</b>	<b>SESSION CHAIR - MICHAEL FRIEDLANDER AND ANNA DEFAZIO</b>	
4.30 – 5.00pm	30mins	More than a biobank! Enabling translational research for ANZGOG trials: presented by Anna DeFazio with 10 mins discussion.		



## 2017 Annual Scientific Meeting

**Dates:** Wednesday 29 March – Saturday 1 April 2017

**Venue:** Grand Hyatt, Melbourne

5.00 – 5.45pm	45mins	<b>POSTER VIEWING SESSIONS</b>	<b>SPONSORED BY ASTRA ZENECA</b>
5.45-6.45pm		<b>SESSION CHAIR - MICHAEL FRIEDLANDER</b>  <b>ANZGOG EVENING SESSION</b>  <b>PRACTICAL GUIDANCE ON THE USE OF OLAPARIB IN WOMEN WITH PSR BRCAM HGSOC</b> - Michael Friedlander, Linda Mileskin, Catherine Shannon	<b>SPONSORED BY ASTRA ZENECA</b> <b>Room: Savoy1</b>
<b>EVENING OPTIONS</b>		<b>FREE EVENING FOR DINNER WITH FRIENDS AND COLLEAGUES IN MELBOURNE</b>	

## Friday 31 MARCH 2017

7.00AM-8.00AM	60 mins	<b>Satellite Symposium : ROCHE BREAKFAST</b> <b>Improving outcomes in HGSOc: From targeted trials to targeted therapies.</b> <b>Booking essential as places are limited.</b> Chair: , <b>Dr George Au-Yeung</b> Peter MacCallum Cancer Centre Speakers: <b>Prof Rob Coleman</b> MD Anderson and <b>Prof Bradley Monk</b> , University of Arizona Cancer Centre	<b>ROOM: SAVOY 3</b>
<b>8.30 – 10.15AM</b>	<b>105MINS</b>	<b>IMPROVING QUALITY OF LIFE</b>	<b>SESSION CHAIR – SUE BREW AND CATH ADAMS</b> <b>ROOM: SAVOY 1</b>
8.30 – 9.45am	75 mins	Panel Session addressing 2 cases studies on Improving Quality of Life: <b>Dr Janine Lombard</b> – Calvary Mater Newcastle, <b>Dr Viet Do</b> – Westmead Hospital, <b>Julia Martin</b> – John Hunter Hospital <b>Kim Hobbs</b> – Westmead Hospital, <b>Dr Bryony Simcock</b> – Christchurch	
9.45 -10.00am	15mins	Lifestyle, side-effects and chemotherapy completion: results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study: <b>Penelope Webb</b>	
10.00 -10.15am	15mins	The Risk of Endometrial Cancer for BRCA1 and BRCA2 Mutation Carriers: <b>Yeh Chen Lee</b>	
<b>10.15 – 10.45am</b>	<b>30 mins</b>	<b>Morning Tea in the Exhibition Area</b>	
<b>10.45 – 11.00am</b>	<b>15 mins</b>	<b>Cancer Australia presentation + Consumer Group Presentation - Helene O'Neill and Consumer Group</b>	
<b>11.00 – 1.00PM</b>	<b>90 MINS</b>	<b>TRIAL CONCEPTS SESSION CHAIRS -</b>	<b>SESSION CHAIR –LINDA MILESHKIN &amp; ALISON DAVIS</b> <b>ROOM: SAVOY 1</b>
11.00 – 11.15am	15 mins	Progress towards the establishment of an Australian Ovarian Cancer Clinical Quality Registry: <b>Rob Rome</b>	
11.15 – 11.25am	10 mins	Trials in Development - ICON9 : <b>Michael Friedlander (PI Linda Mileschkin)</b>	
11.25 - 11.35am	10mins	Trials in Development: STICS AND STONES (just received NHMRC Grant) – PI <b>Kelly Phillip, Chen Lee presenting</b>	
11.35 – 11.45pm	10 mins	Trials in Development: Advaxis AIM2CERV – <b>PI Linda Mileschkin</b>	
11.45 – 11.50pm	5 mins	Questions	
11.50 – 12.05pm	15 mins	NEW CONCEPT 1: A phase II study of a PD-1/PD-L1 blockade in combination with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer: <b>Tarek Meniawy</b>	
12.05 – 12.20pm	15mins	NEW CONCEPT 2: WHAM (What Happens after Menopause)? Impact of risk-reducing bilateral salpingo-oophorectomy on non-cancer outcomes in high-risk women: A multicentre prospective study: <b>Martha Hickey</b>	
12.20 – 12.35pm	15 mins	NEW CONCEPT 3: Assessing Circulation Tumour DNA as a Predictive Biomarker in Type 2 Endometrial Cancer: <b>Rachel Delahunty</b>	



## 2017 Annual Scientific Meeting

**Dates:** Wednesday 29 March – Saturday 1 April 2017

**Venue:** Grand Hyatt, Melbourne

12.35 – 12.50pm	15 mins	NEW CONCEPT 4: Vascular disruption, anti-angiogenesis and immune checkpoint inhibition in high grade serous ovarian cancer: <b>Danny Rischin</b>
12.50 – 1.00pm	10 mins	NEW CONCEPTS - Questions and Discussion

## Friday 31 MARCH 2017

1.00 - 2.00pm	60 mins	Lunch in the Exhibition Area			STATEC Trial Meeting (Connaught)	
2.00 – 5.30PM	3 HOURS	SPECIALISED WORKSHOPS				
2.00 – 3.30pm	90mins	<b>1. Concept Development</b>  <b>Savoy 1 Room</b>	<b>2. Consumers Workshop</b> Helene O'Neill  <b>Bristol 1 Room</b> <b>(ANZGOG Data and Laptop)</b>	<b>3. Radiation Oncology</b> GoROC Pearly Khaw, Viet Do  <b>Savoy 3 Room</b> <b>Sponsored by Varian</b>  <b>CHALLENGING CASES IN VULVA CANCER</b>	<b>4. Gynae Nurses</b> Anne Mellon <b>Savoy 2 Room</b>  <b>EDUCATION PROGRAM IN ENDOMETRIAL CANCER</b>	<b>5. Study Coordinators</b> Sue Brew <b>Bristol 2 Rm</b>  <b>PROGRAM – DEVELOPING A SITE BUDGET FOR CLINICAL TRIALS</b>
2.00 – 3.30pm	90 mins	CLINICAL TRIAL INVESTIGATOR MEETINGS				
		<b>STATEC – LYMPHEDEMA TRAINING</b> <b>Connaught: (20pax)</b>				
3.30 – 4.00pm		Afternoon Tea in the Exhibitor Area				
4.00 – 5.30pm	90mins	Workshops continue ...				
4.00 – 5.30pm	90 mins	CLINICAL TRIAL INVESTIGATOR MEETINGS				
		<b>PHAEDRA</b> <b>Connaught: (20pax)</b>				
7.00 – 11.00pm		CONFERENCE DINNER at 'The Residence' at the Grand Hyatt				



## Saturday 1 APRIL 2017

7.00-8.30am	90 mins	<b>RAC 2 Breakfast meeting</b>	<b>ROOM: MAYFAIR 2</b>
8.45 -10.15AM	90MINS	<b>NEW HORIZONS – BENCH TO BEDSIDE</b>	<b>SPONSORED BY ASTRA ZENECA</b>
		<b>SESSION CHAIRS – PAUL COHEN AND JEFF GOH</b>	<b>ROOM: MAYFAIR 1</b>
8.45 – 9.05am	20 mins	Gene expression molecular subtypes in ovarian cancer: the next stop for precision medicine?: <b>David Tan</b>	
9.05 – 9.25am	20 mins	Targeting the Undruggable: Advances and Obstacles in RNAi Therapy: <b>Anil Sood</b>	
9.25 – 9.45am	20mins	Introducing molecular prognostic factors for endometrial cancer into clinical practice - the PORTEC4a experience.: <b>Remi Nout</b>	
9.45 – 10.00am	15 mins	Higher PD-L1 expression predicts poor prognosis in patients with tubo-ovarian high-grade serous carcinoma treated with neoadjuvant chemotherapy: <b>Tarek Meniawy</b>	
10.00 -10.15am	15mins	Serum IL-6 as a predictive biomarker for diagnosis of malignancy in high-grade serous ovarian carcinoma: <b>Nirmala Kampan</b>	
<b>10.15– 10.45am</b>		<b>Morning Tea in the Exhibition Area:</b>	
<b>10.45 – 11.45AM</b>	<b>60 MINS</b>	<b>DEVELOPING STUDIES AND FUNDING WITH ANZGOG</b>	<b>SPONSORED BY ANZGOG</b>
		<b>SESSION CHAIRS – ALISON BRAND AND RAJ ALI MOHAN</b>	
10.45 - 11.00am	15 mins	Developing Studies and Funding Options through ANZGOG: <b>Alison Brand</b>	
11.00 – 11.10am	10 mins	Ovarian TTWG: <b>Philip Beale</b>	
11.10 – 11.20am	10 mins	Endometrial TTWG: <b>Diana Adams</b>	
11.20 –11.30am	10 mins	Cervix TTWG: <b>Anne Hamilton</b>	
11.30 – 11.45am	15 mins	A review of cervical cancer cares in relation to screening history in New Zealand from 2008-2012: <b>Peter Sykes</b>	
<b>11.45 -12.45PM</b>	<b>60 MINS</b>	<b>DEBATE   TOPIC : SURGERY IS THE ULTIMATE SOLUTION TO ALL GYNAECOLOGICAL CANCER PROBLEMS</b>	<b>ROOM: MAYFAIR 1</b>
		<b>SESSION CHAIRS - ALISON BRAND AND RAJ ALI MOHAN</b>	
		<b>Rob Coleman &amp; Julie Lamont</b> (affirmative) V <b>Pearly Khaw &amp; Andrew Dean</b> (negative)	
<b>12.45 – 12.50pm</b>	<b>5 mins</b>	<b>Thank you to delegates – ANZGOG Chair, Alison Brand</b>	
<b>12.50 – 1.30pm</b>	<b>40 mins</b>	<b>Light Lunch available</b>	<b>[Buses depart from 1.30pm to Airport]</b>

**POST CONFERENCE AFTERNOON ACTIVITIES**
**Saturday 1 APRIL 2017**

<b>2.00PM -4.30PM</b>		<b>CONSUMER INFORMATION SESSION COLLABORATIVE PRESENTATION BY OVARIAN CANCER AUSTRALIA AND ANZGOG</b>	<b>ROOM: MAYFAIR 1</b>
	<i>5 mins</i>	Introduction	
	<i>30 mins</i>	Immunotherapy as an Ovarian Cancer Treatment: <b>Tarek Meniawy</b>	
	<i>15 mins</i>	Q & A	
<b>3.05pm-3.30pm</b>		<b>Afternoon Tea sponsored by the Grand Hyatt</b>	
	<i>15 mins</i>	Participating in a Clinical Trial: <b>Emma Burt</b>	
	<i>20 mins</i>	Finding New Cancer Treatments & the Importance of Clinical Trials: <b>Linda Mileshkin</b>	
	<i>10 mins</i>	Q & A	
	<i>10 mins</i>	Survivors Teaching Students: Saving Women's Lives: <b>Bronwyn Grout</b>	